Working… Menu

Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (CIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01828008
Recruitment Status : Unknown
Verified January 2013 by Han weidong, Chinese PLA General Hospital.
Recruitment status was:  Not yet recruiting
First Posted : April 10, 2013
Last Update Posted : April 10, 2013
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : May 2015
Estimated Study Completion Date : May 2015